Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $180M | $958M |
| Revenue growth | — | — | — | — | — | — | — | — | — | 432.1% |
| Operating income | -$25.2M | -$32.1M | -$40.7M | -$95.0M | -$207M | -$242M | -$294M | -$380M | -$498M | -$300M |
| Operating margin | — | — | — | — | — | — | — | — | -276.4% | -31.3% |
| Net income | -$26.4M | -$31.2M | -$32.8M | -$83.9M | -$202M | -$242M | -$295M | -$374M | -$466M | -$288M |
| Net margin | — | — | — | — | — | — | — | — | -258.6% | -30.1% |
| EPS (diluted) | -$5.07 | -$2.54 | -$2.22 | -$5.45 | -$13.09 | -$14.63 | -$17.23 | -$19.99 | -$21.90 | -$12.85 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$17.6M | -$22.3M | -$25.5M | -$41.6M | -$158M | -$184M | -$225M | -$324M | -$456M | -$190M |
| Capital expenditures | $3.00K | $125K | $22.0K | $172K | $334K | $209K | $217K | $1.48M | $1.46M | $467K |
| Free cash flow | -$17.6M | -$22.4M | -$25.5M | -$41.8M | -$158M | -$184M | -$225M | -$326M | -$457M | -$190M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $19.1M | $149M | $57.4M | $46.7M | $54.0M | $36.3M | $332M | $99.9M | $100M | $199M |
| Total assets | $41.2M | $192M | $485M | $442M | $287M | $273M | $363M | $641M | $1.04B | $1.26B |
| Total liabilities | $4.80M | $10.1M | $8.44M | $25.5M | $47.0M | $77.2M | $165M | $235M | $288M | $657M |
| Long-term debt | — | — | — | — | — | $0.00 | $49.3M | $115M | $118M | $340M |
| Shareholders' equity | $36.4M | $182M | $477M | $417M | $240M | $196M | $197M | $405M | $754M | $603M |
| Retained earnings | -$75.3M | -$106M | -$139M | -$223M | -$425M | -$667M | -$963M | -$1.34B | -$1.80B | -$2.09B |
| Shares (wtd avg diluted) | 12.0M | 14.2M | 15.4M | 15.4M | 15.4M | 16.5M | 17.1M | 18.7M | 21.3M | 22.4M |
Every figure is extracted from MADRIGAL PHARMACEUTICALS, INC.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.